Intelligence · Clinical Development
Pipeline search results
Programs matching “placebo” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 588 pipeline programs matching "placebo" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
ISIS CRP Rx or Placebo
IONIS PHARMACEUTICALS INC
Rheumatoid Arthritis
1 trial -
Itacitinib, placebo of itacitinib 100mg
Pari Pharma GmbH
Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening
1 trial -
Itepekimab, Matched placebo for test product
Sanofi-aventis Healthcare Pty Ltd
Bronchiectasis
1 trial -
JTT-861, Placebo tablet for JTT-861
Lacuna Pharma Pty Ltd
Heart Failure (Heart Failure with Reduced Ejection Fraction)
1 trial -
Jakavi 15 mg tablets, Placebo of Jakavi 15mg
Pari Pharma GmbH
Inclusion body Myositis
1 trial -
Ladarixin, Placebo to match Ladarixin
Dompe' Farmaceutici S.p.A.
Recent onset Type 1 Diabetes
1 trial -
MEDI0618, Placebo to match MEDI0618
AbbVie Deutschland GmbH & Co. KG
Migraine
1 trial -
METFORMIN , Placebo 515
Pari Pharma GmbH
Portal hypertension (PHT) and consequences in complications of cirrhosis
1 trial -
MK-2060, Placebo to MK-2060
Merck Sharp and Dohme
Prevention of arteriovenous graft thrombosis
1 trial -
MLN1202 Placebo
Takeda
Diabetic Nephropathy
1 trial -
MLS-101-206
Mineralys Therapeutics
Chronic Kidney Disease
1 trial -
Match placebo to test product, Balinatunfib
Sanofi-aventis Healthcare Pty Ltd
Crohn's disease
1 trial -
Matched Placebo
Novo Nordisk A/S
Mechanical allodynia
1 trial -
Matched placebo for test product, Itepekimab
Sanofi-aventis Healthcare Pty Ltd
Respiratory tract diseases
1 trial -
Matched placebo for test product, SAR444336
Sanofi-aventis Healthcare Pty Ltd
Digestive system diseases
1 trial -
Matching Placebo
Cyclerion Therapeutics
Diabetes Mellitus, Type 2
1 trial -
Matching film-coated placebo tablet
Bioprojet Pharma
Obsessive compulsive disorder
1 trial -
Matching orodispersible placebo tablet
Bioprojet Pharma
Eosinophilic esophagitis
1 trial -
Matching placebo
BRIGHT MINDS BIOSCIENCES INC.
Familial Dysautonomia
1 trial -
Mivelsiran, Placebo
Alnylam Netherlands B.V.
Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain
1 trial -
NKTR-358, Placebo
Nektar Therapeutics UK Limited
Alopecia Areata
1 trial -
NMD670, Placebo
Lacuna Pharma Pty Ltd
Charcot-Marie-Tooth Disease Type 1 and Type 2
1 trial -
Namodenoson, Matching placebo for namodenoson
Can-Fite BioPharma
Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis
1 trial -
Natrunix with MTX placebo (+folate)
XBiotech Germany GmbH
Rheumatoid Arthritis
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.